How ridiculous. OSL down 30% on the back of a completely unrelated trial from a different company using a different product in a different patient group with different end points. Fickle.
Impact of Sirflox failure to meet primary end point, page-3
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $52.97M | |||
| Open | High | Low | Value | Volume |
| 1.4¢ | 1.4¢ | 1.3¢ | $56.50K | 4.041M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 12011630 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 6141425 | 9 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| OSL (ASX) Chart |